
Opinion|Videos|August 23, 2024
Clinical scenario 1 - BRAFKIAA-1549 fusion
Author(s)Jason Fangusaro, MD
The panel examines a specific patient case, offering detailed insights into their decision-making process and treatment approaches for patients with pediatric low-grade gliomas (pLGG).
Advertisement
Episodes in this series

- Of the possible options, what treatment approach would you select for this patient?
- What key clinical or patient-specific factors informed this choice?
- Please consider and discuss alternate scenarios:
- What if this patient had received frontline chemotherapy (instead of selumetinib) and then progressed? How would this impact your treatment decision?
- What if the patient was currently on a MEKi, would you switch?
Advertisement
Related to this article

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.

VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.

EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.

IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.

Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.

Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple Myeloma
4
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
5

